Insider Selling: Whitehawk Therapeutics (NASDAQ:WHWK) Insider Sells 50,000 Shares of Stock

Key Points

• Insider sale: Director Bryan Ball sold 50,000 shares on April 9 at an average price of $3.57 to cover tax withholding on vested equity, reducing his ownership by 8.73% to 522,551 shares (disclosed via SEC Form 4).
• Stock and fundamentals: WHWK traded up about 2.4% to $3.47, has a market cap of roughly $163.8 million and a P/E of 7.38, with a 52-week range of $1.39–$4.48.
• Analyst and institutional view: Analysts are mixed (two Buys, one Hold, one Sell) with an average target of $6.50, while institutional investors own about 52.08% of the company after several large new stakes were reported.

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) insider Bryan Ball sold 50,000 shares of the company's stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $3.57, for a total transaction of $178,500.00. Following the completion of the transaction, the insider owned 522,551 shares in the company, valued at approximately $1,865,507.07. This trade represents a 8.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Bryan Ball also recently made the following trade(s):

• On Friday, April 10th, Bryan Ball sold 6,596 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.43, for a total transaction of $22,624.28.
• On Monday, March 2nd, Bryan Ball sold 1,834 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $6,070.54.

Whitehawk Therapeutics Stock Up 2.4%

Shares of WHWK stock traded up $0.08 during trading on Monday, hitting $3.47. The company had a trading volume of 143,959 shares, compared to its average volume of 178,839. The stock's 50-day moving average is $3.36 and its two-hundred day moving average is $2.73. The stock has a market capitalization of $163.78 million, a price-to-earnings ratio of 7.38 and a beta of 0.57. Whitehawk Therapeutics, Inc. has a 52 week low of $1.39 and a 52 week high of $4.48.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Wall Street Analysts Forecast Growth

WHWK has been the topic of a number of recent research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research report on Friday, March 27th. Oppenheimer initiated coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an "outperform" rating and a $6.00 price target on the stock. JonesTrading initiated coverage on shares of Whitehawk Therapeutics in a research report on Monday, December 22nd. They set a "buy" rating and a $7.00 price target on the stock. Finally, Wall Street Zen cut shares of Whitehawk Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $6.50.

Institutional Trading of Whitehawk Therapeutics

A number of institutional investors have recently made changes to their positions in WHWK. Orbimed Advisors LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at approximately $7,915,000. Suvretta Capital Management LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at approximately $7,030,000. Acuta Capital Partners LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at approximately $6,480,000. Avoro Capital Advisors LLC purchased a new stake in shares of Whitehawk Therapeutics during the third quarter valued at approximately $5,414,000. Finally, KVP Capital Advisors LP purchased a new stake in shares of Whitehawk Therapeutics during the fourth quarter valued at approximately $5,242,000. Hedge funds and other institutional investors own 52.08% of the company's stock.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.